ArticleFrontiers in immunology2026
Appraisal of primary immunodeficiencies in Latin America and the Caribbean using the IPOPI PID Life Index - where are we now?
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Analyse the implementation of the 6 Principles of Care (PoC) for primary immunodeficiencies (PIDs) in Latin America and the Caribbean countries. Methodology: Data was extracted from the IPOPI PID Life Index, an interactive tool measuring how it is to live with a PID in the 13 countries in Latin America and the Caribbean (Argentina, Bolivia, Brazil, Chile, Ecuador, El Salvador, Honduras, Mexico, Paraguay, Peru, Puerto Rico, Uruguay and Venezuela). Results: Care for PIDs in the region varies greatly. Low diagnostic rates and limited diagnostic test options are a reality for the region. Almost all countries provide certain therapies for the treatment of PIDs, mostly anti-infectious therapies, immunoglobulin replacement therapies and vaccines. Biological therapies and curative treatments are less frequent in the countries covered. Universal health coverage for people living with PIDs remains heterogeneous and incomplete. Specialised centres and registries are also heterogeneously implemented. National organisations representing patients with PIDs exist in almost all countries, mainly focussing on general and medical awareness raising, and patient support through social activities. Discussion and conclusion: PID care in Latin America and the Caribbean is steadily becoming a reality for many people living with PID. There have been significant improvements in terms of diagnosis, treatment and care in the region over the past decades. Still, there are significant inequalities across the different countries for the 6 PoCs for PID analysed. Joint efforts of medical specialists and patient organizations must continue to ensure an optimal environment for people living with PIDs in the region.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.